Aberrant methylation and loss of expression of O6-methylguanine- DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma

Pathology International

Volumn 55, Issue 6, 2005, Pages 303-309

  Furonaka, Osamu ^a   Takeshima, Yukio ^a   Awaya, Hirokazu ^a   Kushitani, Kei ^a   Kohno, Nobuoki ^a   Inai, Kouki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Aberrant methylation; Adenocarcinoma; Multistep carcinogenesis; O 6 methylguanine DNA methyltransferase (MGMT); Squamous cell carcinoma

Indexed keywords

ALKYLATING AGENT; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADULT; AGED; ARTICLE; CELL PROTECTION; CORRELATION ANALYSIS; DNA METHYLATION; FEMALE; GENE; GENE INACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MGMT GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION;

EID: 21344457722     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2005.01830.x     Document Type: Article

References (39)

1. Gardar AF, Minna JD. Molecular detection of early lung cancer. J Natl Cancer Inst 1999; 91: 299-301.
2. Nishisaka T, Takeshima Y, Inai K. Evaluation of p53 gene mutation and loss of heterozygosity of 3p, 9p and p17 in precancerous lesions of 29 lung cancer patients. Hiroshima J Med Sci 2000; 49: 109-16.
3. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. World Health Organization Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours, 3rd edn. Berlin: Springer, 1999.
4. Kitamura H, Kameda Y, Nakamura N et al. Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma: Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am J Surg Pathol 1996; 20: 553-62.
5. Kitamura H, Kameda Y, Nakamura N et al. Proliferative potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. Am J Pathol 1995; 146: 876-87.
6. Noguchi M, Morikawa A, Kawasaki M et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75: 2844-52.
7. Kitamura H, Kameda Y, Ito T, Hayashi H. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol 1999; 111: 610-22.
8. Yamasaki M, Takeshima Y, Fujii S et al. Correlation between genetic alterations and histopathological subtypes in bronchiolo-alveolar carcinoma and atypical adenomatous hyperplasia of the lung. Pathol Int 2000; 50: 778-85.
9. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91: 1194-210.
10. Smith LE, Denissenko MF, Bennett WP et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000; 92: 803-11.
11. Kawano R, Takeshima Y, Inai K. Effects of K-ras gene mutations in the development of lung lesions induced by 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl) -1-butanone in A/J mice. Jpn J Cancer Res 1996; 87: 44-50.
12. 6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 6119-29.
13. Coulondre C, Miller JH. Genetic studies of the lac represser IV. Mutagenic specificity in the lacl gene of Escherichia coli. J Mol Biol 1977; 117: 577-606.
14. Gerde P, Muggenburg BA, Thornton-Manning JR, Lewis JL, Pyon KH, Dahl AR. Benzo[a]pyrene at an environmentally relevant dose is slowly absorbed by, and extensively metabolized in, tracheal epithelium. Carcinogenesis 1997; 18: 1825-32.
15. Gerde P, Muggenburg BA, Stephens T, Lewis JL, Pyon KH, Dahl AR. A relevant dose of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is extensively metabolized and rapidly absorbed in the canine tracheal mucosa. Cancer Res 1998; 58: 1417-22.
16. Hussain SP, Harris CC. p53 mutation spectrum and load: The generation of hypotheses linking the exposure of endogeneous or exogeneous carcinogens to human cancer. Mutat Res 1999; 428: 23-32.
17. Ahrendt SA, Chow JT, Yang SC et al. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res 2000; 60: 3155-9.
18. Hollstein M, Shomer B, Greenblatt M et al. Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation. Nucleic Acids Res 1996; 24: 141-6.
19. 6- Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res 2001; 61: 8113-17.
20. 6-methylguanine-DNA methyltransferase gene: More common in lung adenocarcinomas.from never-smokers than smokers and associated with tumor progression. Cancer Res 2003; 63: 4842-8.
21. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-17.
22. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002; 196: 1-7.
23. 6-methylguanine-DNA methyltransferase expression in human lung carcinomas. Carcinogenesis 1998; 19: 1247-50.
24. 6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem 1994; 269: 17228-37.
25. 6-methylguanine-DNA methyltransferase gene. Cancer Res 1997; 57: 3672-7.
26. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcrip-start site and silencing of the gene. Mol Cell Biol 1997; 17: 5612-19.
27. 6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis 1986; 7: 745-9.
28. 6-methylguanine-DNA methyltransferase gene MGMT in MER+ and MER- human tumor cells. Cancer Res 1990; 50: 7908-11.
29. 6-methylguanine DNA methyltransferase (MGMT) mRNA levels in Mer+ and Mer- human tumor cell lines containing the MGMT gene by the polymerase chain reaction technique. Cancer Commun 1990; 2: 13-20.
30. Osamu F, Yukio T, Hirokazu A, Hajime I, Nobuoki K, Kouki I. Aberrant methylation of p14ARF, p15INK4b and p16INK4a genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol Int 2004; 54: 549-55.
31. Divine KK, Pulling LC, Marron-Terada PG et al. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int J Cancer 2005; 114: 400-5.
32. 6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13: 967-75.
33. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61: 249-55.
34. 6-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: Associations with clinical outcome. Clin Cancer Res 2003; 9: 223-7.
35. Chan EC, Lam SY, Tsang KW et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: Patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clin Cancer Res 2002; 8: 3741-6.
36. Topaloglu O, Hoque MO, Tokumaru Y et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 2004; 10: 2284-8.
37. 6-methylguanine-DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers. Jpn J Cancer Res 2002; 93: 184-9.
38. Yatabe Y, Mitsudomi T, Takahashi T. Maspin expression in normal lung and non-small-cell lung cancers: Cellular property-associated expression under the control of promoter DNA methylation. Oncogene 2004; 23: 4041-9.
39. Kim DH, Nelson HH, Wiencke JK et al. p16 (INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001; 61: 3419-24.